Imec signs licensing agreement with miDiagnostics to commercialize its patented technology for fast and reliable COVID-19 diagnosis based on exhaled breath

Revealed: Oct. 14, 2021 at 10:39 AM CDT|Up to date: 22 minutes in the past

LEUVEN, Belgium, Oct. 14, 2021 /PRNewswire/ — Imec, the world’s main analysis and innovation hub in nanoelectronics and digital expertise, and miDiagnostics, a spin-off of imec in collaboration with Johns Hopkins College specialised within the growth of point-of-care assessments for screening, diagnosing and monitoring a variety of well being situations, announce that they’ve signed a non-exclusive licensing settlement for imec’s patented expertise whereby aerosols and droplets from exhaled breath are captured for screening for viral RNA via miDiagnostics ultrafast PCR expertise. The settlement permits miDiagnostics to kickstart the commercialization of a COVID-19 breathalyzer (versus classical COVID-19 testing strategies based mostly on blood, saliva or a pattern from the nostril/throat cavity).

A demonstration sample of the proof-of-concept breath sampler, developed by imec.
An indication pattern of the proof-of-concept breath sampler, developed by imec.

Previously 12 months, imec developed a breath sampler based mostly on imec’s distinctive chip expertise, and carried out medical research with the college hospital and college of Leuven exhibiting that imec’s breath sampler is able to capturing the SARS-CoV-2 virus in exhaled air, and detecting the viral RNA rapidly and reliably. Additionally, imec developed a sampling instrument integrating the breath sampling expertise and imec’s ultra-fast PCR-test, and optimized the robustness and ease of use, to realize a functioning proof-of-concept so far.

“I word with nice pleasure that we now have run a powerful course previously months,” says Luc Van den hove, CEO at imec. “Now we have succeeded in reworking a promising idea and groundbreaking expertise right into a practical proof-of-concept that has handed each consumer assessments and medical research. That is the primary time that we now have gone this far within the growth of our chip expertise in the direction of commercialization. With this proof-of-concept, we are able to reveal a lot nearer to the market the added worth of our expertise, whereas considerably lowering the time-to-market for our companions. The license settlement with miDiagnostics is a crucial milestone for imec: Our breakthrough expertise will assist curb the COVID-19 pandemic within the foreseeable future.”

As COVID-19 will definitely not be the final virus to engulf the world, imec is already wanting additional, by investigating how its patented expertise will also be utilized to diagnose different infectious airborne illnesses. As well as, imec can also be wanting into its software in diagnosing illnesses comparable to most cancers. corporations are welcome to hitch this effort.

“Regardless of the vaccination campaigns, there’s nonetheless an awesome want for accessible and dependable speedy assessments to curb new virus outbreaks or to keep away from pointless quarantine. With our license to imec’s groundbreaking expertise, we goal to make our ultra-fast PCR expertise, which we now use for nasal swabs, additionally appropriate with exhaled air the proper pattern for silicon-based PCR. This primary prototype might be examined on the airport in November in collaboration with Brussels Airport, Ecolog and Eurofins,” says Katleen Verleysen, CEO of miDiagnostics.

“Our analysis investments via imec result in new technological breakthroughs. The interaction between data, analysis and entrepreneurship offers financial and social added worth. With the brand new breathalyzer, we’re additionally making historical past in testing COVID-19. The event of those assessments is of nice significance for public well being. On this manner we can handle this pandemic even higher and improve the consolation for individuals who should be examined. That’s the reason I’m proud that we now have been in a position to assist the event and analysis of imec,” says Flemish Minister of Innovation Hilde Crevits

About imec

Imec is a world-leading analysis and innovation middle in nanoelectronics and digital applied sciences. Imec leverages its state-of-the-art R&D infrastructure and its crew of greater than 5,000 workers and high researchers, for R&D in superior semiconductor and system scaling, silicon photonics, synthetic intelligence, past 5G communications and sensing applied sciences, and in software domains comparable to well being and life sciences, mobility, {industry} 4.0, agrofood, good cities, sustainable vitality, training… Imec unites world-industry leaders throughout the semiconductor worth chain, Flanders-based and worldwide tech, pharma, medical and ICT corporations, start-ups, and academia and data facilities. Imec is headquartered in Leuven (Belgium), and has analysis websites throughout Belgium, in the Netherlands, Taiwan and the USA, and workplaces in China, India and Japan. In 2020, imec’s income (P&L) totaled 680 million euro.

Additional info on imec will be discovered at

Imec is a registered trademark for the actions of imec Worldwide (IMEC Worldwide, a authorized entity arrange beneath Belgian legislation as a “stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Flemish Authorities), imec the Netherlands (Stichting IMEC Nederland),  imec Taiwan (IMEC Taiwan Co.), imec China (IMEC Microelectronics (Shanghai) Co. Ltd.), imec India (IMEC India Non-public Restricted), imec San Francisco (IMEC Inc.) and imec Florida (IMEC USA Nanoelectronics Design Middle Inc.).

About miDiagnostics

miDiagnostics is utilizing silicon chip expertise which can convey miniaturized, speedy, easy-to-use, lab-quality assessments direct to the affected person and clinician. Combining a nanofluidic processor on a chip and a compact reader, miDiagnostics can measure just about any biomarker from a minimally invasive pattern comparable to drops of fingerprick blood or swabs. The Firm is creating an in depth portfolio of assessments for screening, prognosis and monitoring of a variety of well being situations, together with infectious illnesses. Spun out of the world-leading R&D and innovation hub in nanoelectronics and digital applied sciences, imec, and a analysis collaboration with Johns Hopkins College, the main US analysis and medical centre, miDiagnostics’ aim is to allow quick, complete and cost-effective well being evaluation, no matter location.  Primarily based in Leuven, Belgium, miDiagnostics is a privately held firm created in 2015.


View unique content material to obtain multimedia:


The above press launch was offered courtesy of PRNewswire. The views, opinions and statements within the press launch are usually not endorsed by Grey Media Group nor do they essentially state or replicate these of Grey Media Group, Inc.

Source link


Related Posts

Next Post

Leave a Reply

Your email address will not be published. Required fields are marked *